Three-year experience with NORPLANT subdermal contraception
| Autor: | Francisco Alvarez Sanchez, Olivia McDonald, Janet Stern, Irving Sivin, Elsimar M. Coutinho, Dale N. Robertson, Pentti Holma, Soledad Diaz |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Adult
medicine.medical_specialty Patient Dropouts Adolescent Population Pain Levonorgestrel Intrauterine device Hemoglobins Double-Blind Method Pregnancy Norgestrienone Contraceptive Agents Female Medicine Humans education Menstruation Disturbances Gynecology Drug Implants education.field_of_study Clinical Trials as Topic business.industry Norgestrel Obstetrics and Gynecology Metrorrhagia medicine.disease Intrauterine Devices Copper Irregular menstruation Pregnancy rate Contraceptives Oral Combined Reproductive Medicine Family planning Female medicine.symptom business medicine.drug |
| Zdroj: | Fertility and sterility. 39(6) |
| ISSN: | 0015-0282 |
| Popis: | NORPLANTTM (Laboratorios Gutfol, S.A., Mexico City, Mexico) subdermal implants containing levonorgestrel were accepted by 816 women in a two-phase study initiated in 1975 and augmented in 1978. Through 3 years of first-segment use, acceptors experienced five pregnancies, a cumulative net rate of 0.7 per 100, and a gross pregnancy rate of 1.1 per 100. First-segment continuation at 3 years was at the rate of 44.6 per 100, an annual average of 76 per 100. NORPLANT users experienced irregular menstruation, with high interindividual variation, but with normal average numbers of bleeding days and of bleeding episodes. Hemoglobin levels increased moderately during implant use. The incidence of systolic blood pressure readings above 145 mm Hg or diastolic readings above 95 mm Hg was similar to that observed among users of the TCu 200 intrauterine device enrolled under the same selection criteria in the same clinics between the two phases of the NORPLANT study. Comparative data on pregnancy and other rates are also given for these intrauterine device acceptors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|